Navigation Links
iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
Date:5/11/2009

Results Based on FDA's ECG Data Warehouse and Shared at 2009 Drug Information Association Conference

Rochester, NY (PRWEB) May 11, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development, today announced that the company's Highly Automated QT technology has now been validated against manual or semi-automated measurements made by five leading ECG core laboratories. The data for the analysis comprised a total of six independent Thorough QT (TQT) studies stored in FDA's ECG warehouse. The results of the validation study found the measurements made by Highly Automated QT to be statistically consistent with the measurements made independently and in a blinded fashion by the core laboratories.

"This is an important step for cardiac safety testing," said Sasha Latypova, Executive Vice President at iCardiac. "Given these results, pharmaceutical companies can be confident in using the Highly Automated QT technology in their cardiac safety studies to increase the robustness of their study results, as well as to drive cost reductions in their development process."

The Highly Automated QT technology, which iCardiac has licensed from the University of Rochester, is unique in the industry because it combines advanced ECG signal processing with a quality assurance process involving cardiologists. With this approach, only a small portion of the entire Thorough QT (TQT) dataset requires manual over-reading, thereby generating significant cost and time savings to sponsors while at the same time providing assurance to the regulators regarding data quality.

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision and high cost of the "gold standard" manual QT measurements has lead to efforts toward automating QT interval measurement.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/automatedQT/corelabs/prweb2394714.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
2. VARI researcher chosen for highly competitive Scholar-in-Training Award
3. Dr.Khanna Featured in Highly Respected Trade Journal
4. Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
5. A New, Highly Effective, Non-Narcotic Pain Medication Now Available for Chronic Pain Patients
6. Perlabella Introduces a Highly Concentrated and Affordable Anti-Aging Skin Care Line
7. Yankees Will Become First MLB Team to Integrate Highly Advanced Antimicrobial System
8. Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
9. Pennsylvania Health Department Offers Tips to Prevent Spread of Highly Contagious Norovirus
10. Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market
11. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... 2016 , ... Southern Illinois University School of Dental Medicine ... State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host a ... , They expect to treat approximately 2,000 patients from Illinois, Missouri, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion research programs and ... enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology: